author-photo

James Smothers

GlaxoSmithKline

11

Papers

606

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Abstract 5554: Preclinical characterization of GSK532, a novel STING agonist with potent anti-tumor activity

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments

2018 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (67)
Synergy of TLR4 agonist GSK1795091, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecule OX40 in cancer immunotherapy.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
1192PEvaluation of OX40 receptor density, influence of IgG Isotype and dosing paradigm in anti-OX40-mediated efficacy and biomarker responses with PD-1 blockade

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract A054: In vivo characterization of Ipilimumab T cell modulation and antitumor activity in a tumor bearing humanized NSG mouse model

2016 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (0)
Big opportunities for small molecules in immuno-oncology

2015 Nature Reviews Drug Discovery
Show All
- Source
- Cite
- Save
Citations (244)
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

2015 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (253)
Abstract 644: Novel anti-B cell maturation antigen-monomethyl auristatin F antibody-drug conjugate (GSK2857916) induces potent and selective anti-multiple myeloma activity via enhanced effector function and direct tumor cell killing

2014 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)